

2018
MEDICARE LOCAL COVERAGE DETERMINATION (LCD) - L35710
PROCEDURE CODES: 86152, 86153

MOLDX: Circulating Tumor Cell Marker Assays
For services performed on or after 10-01-2015

DLS TEST CODE AND NAME

51459	CELLSEARCH CIRCULATING TUM-CELLS PROSTATE (Proc Code: 86152 & 86153)
51469	CELLSEARCH CIRCULATING TUMOR BREAST (Proc Code: 86152 & 86153)

This is a NON-coverage policy for the circulating tumor cell (CTC) assay, including but not limited to the CellSearch (Veridex), OnoCEE (Biocept) and PCR (RTPCR) Assays.

CTCs are found in the serum during the metastatic process of solid tumors when cells from a primary tumor invade, detach, disseminate, colonize and proliferate to a distant site. The detection of elevated CTCs during therapy is an indication of disease progression and overall survival in some cancers, however the medical literature does not demonstrate the test findings contribute to an improvement in patient outcomes. Adoption of the test into treatment paradigms and clinical guidelines has not occurred. CTC testing for all malignant diagnoses will be denied as not reasonable and necessary.